TherapeuticsMD, Inc. (TXMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

TherapeuticsMD, Inc. (TXMD) Healthcare & Pipeline Overview

TherapeuticsMD, Inc. is a U.S.-based women's healthcare company specializing in prescription products for dyspareunia, vasomotor symptoms, and contraception, complemented by a prenatal vitamin portfolio. With an active preclinical pipeline, the company focuses on addressing specific health needs within the women's health market through its commercialized offerings and future innovations.

What Is the Investment Thesis for TXMD?

TherapeuticsMD, Inc. operates with a specialized focus on women's healthcare, offering a portfolio of commercialized products and an active preclinical pipeline. The company's current market capitalization stands at $24.3M, reflecting its niche market position within the broader healthcare sector. A notable financial characteristic is its gross margin of 100.0%, indicating strong product economics or efficient cost management relative to revenue. The profit margin is 5.3%, while the return on equity (ROE) is 0.3%, suggesting limited profitability relative to shareholder equity. The debt-to-equity ratio is 21.62, indicating a significant reliance on debt financing, which could impact financial flexibility. A beta of 0.58 suggests lower volatility compared to the broader market. Key growth catalysts include the potential advancement and commercialization of its preclinical pipeline candidates, such as TX-005HR and TX-006HR, which could introduce new revenue streams and expand market share in hormone therapy. Continued adoption of existing products like IMVEXXY, BIJUVA, and ANNOVERA within their respective therapeutic areas also serves as an ongoing value driver. The established prenatal vitamin segment provides a diversified revenue base. However, risks include the high debt-to-equity ratio, the inherent uncertainties of pharmaceutical research and development, and competitive pressures within the women's health market. The company's ability to navigate regulatory pathways and secure market acceptance for pipeline assets will be critical for future value creation.

Based on FMP financials and quantitative analysis

TXMD Key Highlights

Gross Margin of 100.0%: This exceptionally high gross margin indicates strong cost control relative to revenue from product sales, or specific accounting for its revenue streams.

• Specialized Women's Healthcare Focus: The company exclusively targets the women's health market with products for dyspareunia, vasomotor symptoms, contraception, and prenatal nutrition.
• Active Preclinical Pipeline: TherapeuticsMD is developing multiple hormone therapy candidates (TX-005HR, TX-006HR, TX-007HR, TX-008HR, TX-009HR) aimed at future market expansion.
• Debt-to-Equity Ratio of 21.62: This metric highlights a substantial reliance on debt financing relative to equity, which can impact financial flexibility.
• Market Capitalization of $24.3M: Reflects its position as a smaller-cap company within the broader healthcare sector, potentially offering higher growth potential but also increased volatility.

Who Are TXMD's Competitors?

TXMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are TXMD's Key Strengths?

Specialized focus on women's healthcare, addressing specific and prevalent conditions with targeted products.

• Diverse product portfolio including commercialized drugs (IMVEXXY, BIJUVA, ANNOVERA) and prescription prenatal vitamins.
• High gross margin of 100.0%, indicating strong product economics or efficient cost of goods sold.
• Active preclinical pipeline for future hormone therapy innovations, signaling long-term growth potential.

What Are TXMD's Weaknesses?

Small market capitalization of $24.3M, potentially limiting access to significant capital for R&D or market expansion.

• High debt-to-equity ratio of 21.62, indicating significant financial leverage and potential sensitivity to interest rate changes.
• Low return on equity (ROE) of 0.3%, suggesting inefficient use of shareholder equity to generate profits.
• Small employee count (1 employee), which might imply heavy reliance on external resources or a very lean operational structure that could impact scalability.

What Could Drive TXMD Stock Higher?

TXMD catalyst: Potential regulatory milestones or clinical trial updates for preclinical pipeline candidates (TX-005HR, TX-006HR, TX-007HR, TX-008HR, TX-009HR), which could de-risk future product development.

• Continued market penetration and adoption of IMVEXXY for moderate-to-severe dyspareunia, driving consistent revenue growth.
• Increased prescription rates and market acceptance for BIJUVA, a bio-identical hormone therapy for vasomotor symptoms, expanding its patient base.
• Expansion of the user base for ANNOVERA, the ring-shaped contraceptive vaginal system, through targeted marketing and patient education efforts.
• Growth in sales and distribution of the branded and generic prescription prenatal vitamin portfolio, contributing to stable revenue streams.

What Are the Key Risks for TXMD?

Financial-distress signal — its Altman Z-Score of -34.17 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-0.8%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 6 reported quarters.
• High debt-to-equity ratio of 21.62, which could limit financial flexibility, increase interest expenses, and pose refinancing challenges.
• Intense competition in the women's healthcare market from established pharmaceutical companies with greater resources and market share.
• Clinical trial failures, delays, or unexpected safety concerns for preclinical pipeline products, impacting future revenue streams and R&D investment.
• Regulatory challenges and the complex, lengthy approval process for new pharmaceutical products, which can lead to significant delays and costs.
• Market acceptance issues or slower-than-anticipated adoption rates for existing or new products, potentially impacting sales forecasts and profitability.

What Are the Growth Opportunities for TXMD?

• Expansion of IMVEXXY Market Penetration: IMVEXXY, designed for moderate-to-severe dyspareunia, addresses a significant unmet need in postmenopausal women. The market for vaginal atrophy and related symptoms is substantial, with millions of women experiencing these conditions. Increased physician awareness and patient adoption, driven by targeted marketing and clinical evidence, could significantly expand IMVEXXY's sales. As of 2026, continued efforts to educate healthcare providers on the benefits of IMVEXXY as a non-estrogen alternative could capture a larger share of this growing market, potentially leading to sustained revenue growth over the next 3-5 years.
• Increased Adoption of BIJUVA for Vasomotor Symptoms: BIJUVA offers a bio-identical hormone therapy combination for moderate-to-severe vasomotor symptoms, a common and often debilitating aspect of menopause. The global menopausal hormone therapy market is projected to continue growing, driven by an aging population. TherapeuticsMD can capitalize on this by emphasizing BIJUVA's bio-identical formulation, which may appeal to a segment of patients and prescribers seeking natural hormone options. Strategic partnerships and expanded insurance coverage could further accelerate adoption, contributing to revenue growth over the medium term (2-4 years) as more women seek effective symptom management.
• Commercial Success of ANNOVERA Contraceptive System: ANNOVERA, a ring-shaped contraceptive vaginal system, represents an innovative long-acting reversible contraceptive (LARC) option. The global contraceptive market is robust, with a consistent demand for convenient and effective birth control methods. ANNOVERA's unique delivery mechanism and extended use profile could position it favorably against daily pills or shorter-acting methods. Focused marketing to gynecologists and family planning clinics, coupled with patient education on its benefits, could drive significant uptake. This product has the potential to be a key revenue driver for TherapeuticsMD over the next 5-7 years, capturing market share in the competitive contraception landscape.
• Advancement of Preclinical Pipeline Candidates: TherapeuticsMD's preclinical pipeline, including TX-005HR (progesterone-alone transdermal cream), TX-006HR (estradiol and progesterone transdermal cream), TX-007HR/TX-008HR (transdermal patches), and TX-009HR (oral formulation), represents future growth potential. Successful progression of these candidates through clinical trials and eventual regulatory approval could introduce novel, differentiated hormone therapies to the market. Each successful launch would open new revenue streams and expand the company's therapeutic footprint. This long-term growth opportunity (5-10+ years) is contingent on successful R&D, but it positions the company for sustained innovation in women's health.
• Growth in the Prenatal Vitamin Market Segment: The company's portfolio of branded and generic prescription prenatal vitamins (vitaTrue, vitaPearl, vitaMedMD, BocaGreenMD Prena1) provides a stable, recurring revenue stream. The prenatal vitamin market is consistently driven by birth rates and increasing awareness of maternal and fetal health. TherapeuticsMD can leverage its existing distribution channels to expand its market share in this segment. Introducing new formulations or expanding marketing efforts to obstetricians and gynecologists could lead to incremental growth. This segment offers a less volatile revenue base compared to prescription pharmaceuticals, contributing to overall company stability and growth over the next 1-3 years.

What Threats Does TXMD Face?

• Intense competition from larger pharmaceutical companies with greater R&D budgets, marketing resources, and broader product portfolios.
• Significant regulatory hurdles and the inherent risk of clinical trial failures or delays for pipeline products, impacting future market entry.
• Market acceptance challenges or slower-than-anticipated adoption rates for existing or new products in a crowded therapeutic area.
• Reliance on wholesale and retail distributors, which could impact pricing power, distribution control, and market access.

What Are TXMD's Competitive Advantages?

• Specialized Product Portfolio: Focus on women's healthcare with specific, FDA-approved formulations like bio-identical hormone therapy and unique contraceptive delivery systems.
• Established Market Presence: Commercialized products (IMVEXXY, BIJUVA, ANNOVERA) have gained regulatory approval and are distributed across the U.S. market.
• Active R&D Pipeline: Ongoing preclinical projects aim to develop new hormone therapy options, potentially leading to future proprietary products and market differentiation.
• Diversified Revenue Streams: The combination of prescription pharmaceuticals and a stable prenatal vitamin segment offers a broader and potentially more resilient revenue base.

What Does TXMD Do?

TherapeuticsMD, Inc. is a dedicated women's healthcare company operating exclusively within the United States, committed to addressing various health needs specific to women across different life stages. Founded in 2008 and headquartered in Boca Raton, Florida, the company has strategically evolved to offer a focused portfolio of prescription pharmaceutical products and a comprehensive line of prescription prenatal vitamins. Its core commercial offerings include IMVEXXY, a product specifically formulated for the treatment of moderate-to-severe dyspareunia, a condition characterized by painful intercourse often experienced by postmenopausal women. Another key product is BIJUVA, a bio-identical hormone therapy that combines 17ß-estradiol and progesterone, designed to alleviate moderate-to-severe vasomotor symptoms, commonly known as hot flashes, which are prevalent during menopause. Furthermore, TherapeuticsMD provides ANNOVERA, an innovative ring-shaped contraceptive vaginal system, offering women a long-acting reversible contraception option with a unique administration profile. Beyond its commercially available products, TherapeuticsMD maintains an active preclinical pipeline, signaling its commitment to continuous innovation in women's health. This pipeline includes several investigational hormone therapy candidates such as TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. These projects aim to expand the company's therapeutic reach and offer new treatment modalities for various women's health conditions. In addition to its pharmaceutical segment, TherapeuticsMD also manufactures and distributes a range of branded and generic prescription prenatal vitamins under recognized names like vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1. The company's distribution model involves selling its prescription pharmaceutical products and prenatal vitamin products primarily to wholesale distributors and retail pharmacy distributors across the United States, ensuring broad access to its specialized offerings. This integrated approach positions TherapeuticsMD as a key player in the women's health sector, addressing both therapeutic and nutritional needs with a focused and evolving product portfolio.

What Products and Services Does TXMD Offer?

• Develops and commercializes prescription pharmaceutical products specifically for women's health in the U.S.
• Offers IMVEXXY for the treatment of moderate-to-severe dyspareunia (painful intercourse).
• Provides BIJUVA, a bio-identical hormone therapy combining 17ß-estradiol and progesterone for moderate-to-severe vasomotor symptoms (hot flashes).
• Markets ANNOVERA, a ring-shaped contraceptive vaginal system.
• Engages in preclinical development of various hormone therapy candidates, including transdermal creams, patches, and oral formulations.
• Manufactures and distributes branded and generic prescription prenatal vitamins under brands like vitaTrue and vitaMedMD.
• Sells its pharmaceutical and vitamin products to wholesale distributors and retail pharmacy distributors.

How Does TXMD Make Money?

• Generates revenue from the sale of its proprietary prescription pharmaceutical products targeting women's health conditions.
• Earns revenue from the sale of its unique ring-shaped contraceptive vaginal system.
• Derives revenue from the manufacturing and distribution of branded and generic prescription prenatal vitamins.
• Utilizes a business-to-business model, selling products to wholesale distributors and retail pharmacy networks for onward distribution to patients.

What Industry Does TXMD Operate In?

TherapeuticsMD, Inc. operates within the dynamic and specialized segment of the U.S. women's healthcare industry, an area characterized by evolving patient needs, technological advancements, and significant market potential. The company's focus on conditions such as moderate-to-severe dyspareunia, vasomotor symptoms, and contraception places it in therapeutic markets that address widespread health issues affecting millions of women. The market for hormone therapy, for instance, continues to be substantial, driven by an aging female population seeking relief from menopausal symptoms. Similarly, the demand for diverse and effective contraceptive options remains robust. TherapeuticsMD competes with both established pharmaceutical giants and smaller, innovative biotech firms that also target women's health. Its competitive landscape includes companies offering similar hormone replacement therapies, vaginal health products, and contraceptive solutions. The company differentiates itself through specific formulations like bio-identical hormone therapy (BIJUVA) and unique delivery systems (ANNOVERA), alongside its comprehensive prenatal vitamin portfolio. The industry is influenced by regulatory approvals, patent expirations, and the ongoing need for research and development to bring novel solutions to market, all of which shape TherapeuticsMD's strategic positioning.

Who Are TXMD's Key Customers?

• Women experiencing moderate-to-severe dyspareunia seeking treatment.
• Women experiencing moderate-to-severe vasomotor symptoms (hot flashes) seeking hormone therapy.
• Women seeking a long-acting, ring-shaped contraceptive vaginal system.
• Pregnant women and those planning pregnancy who require prescription prenatal vitamins.
• Wholesale pharmaceutical distributors and retail pharmacy chains in the United States.

The most recent 12 insider filings for TherapeuticsMD, Inc. break down as 1 sales and 11 purchases. On net that is roughly 113K shares acquired (about $94K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: TherapeuticsMD, Inc.

Revenue for TherapeuticsMD, Inc. came in at $869K during Q2 FY2026, a 20.0% improvement versus the preceding quarter. The company recorded net income of $155K, with diluted EPS of $0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, TXMD averaged $-0.00 in diluted EPS.

TXMD Valuation & Market Position

With a $24.3M market cap, TherapeuticsMD, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TXMD's quantitative score of 25/100 is below the peer average of 46/100.

Return on equity for TherapeuticsMD, Inc. stands at -0.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 12.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.

TherapeuticsMD, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -34.17 places it in the distress zone, a signal of elevated financial risk.

TherapeuticsMD, Inc. has missed Wall Street's EPS estimate in 4 of its last 6 reported quarters — a mixed record worth weighing. Reported results have landed about 117.3% below estimates on average.

Company Profile

TherapeuticsMD, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO Marlan D. Walker. TXMD has traded publicly since 2007.

TXMD Financials

TXMD Latest News

TXMD Analyst Consensus

TXMD MoonshotScore

TherapeuticsMD, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources